Help Us Protect Access to Sexual and Reproductive Health Care Today!
Jul 16
Written by Meghan Hynes This Pearl is the second part of a three-part String of Pearls series that examines the effects of different substances on fetal development and recommends harm reduction strategies to reduce risks involved with substance use during pregnancy. You can read the first part on our website. Numerous factors over recent years…
Jun 28
This guide provides illustrations and descriptions of different options for pelvic exams. This resource was informed by Table Manners: A Guide to the Pelvic Examination for Disabled Women and Health Care Providers and conversations with disability justice advocates. Illustrations for this resource were created by Rachel Litchman. This resource is also available as a poster.
Jun 25
Written by Sally Rafie, PharmD, BCPS, APh, FCCP, FCPhA Primary care clinicians can prescribe mifepristone and misoprostol to be dispensed by a pharmacy as a means to increase access to medication abortion. Patients can fill the prescriptions at a certified brick-and-mortar or mail-order pharmacy of their choice. In January 2023, pharmacies were granted the ability…
Jun 18
Written by Meghan Hynes Although health care professionals and institutions are evolving from treating addiction as a moral failing to treating it as a chronic disease in recent years, substance use during pregnancy remains misunderstood and heavily stigmatized. This stigmatization can negatively affect how health care professionals perceive patients with substance use disorders (SUDs) and…
Jun 05
Protocol and guidance for providing a medication abortion using mifepristone and misoprostol without ultrasound.
Apr 23
This resource from the University of California San Francisco compares tubal sterilization with long-acting reversible contraceptive (LARC) methods like the IUD and Implant.
Apr 23
Written by Brandy Bautista This article was published in April 2024, before the Supreme Court released its ruling in Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration on June 13th. In its ruling, the Supreme Court unanimously rejected the challenge to mifepristone access. While we celebrate this decision, we know this will not…
Apr 16
By Joi C. Spaulding MD, MS Opill, a daily progestin-only birth control pill (POP), was first approved for over-the-counter (OTC) use by the United States Food and Drug Administration (FDA) on July 13, 2023. As of March 2024, the pill is now available to people of all ages to purchase at retailers online and in…
Apr 16
This poster compares birth control choices based on efficacy, cost, side effects, and other patient-focused factors.
Mar 26
Written by Rebecca Wang, JD, Senior Legal Support Counsel and Lauren Paulk, JD, Senior Research Counsel Mandatory reporting is not an evidence-based practice. Neither is punishing providers for a failure to report. Still, healthcare provider reports to Child Protective Services of infants have increased substantially over the last decade.ยน This is despite only two states…